TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity

Journal of Virology

Volumn 87, Issue 1, 2013, Pages 257-272

  Uchil, Pradeep D ^a   Hinz, Angelika ^a   Siegel, Steven ^a   Coenen Stass, Anna ^a   Pertel, Thomas ^b   Luban, Jeremy ^b,c   Mothes, Walther ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LIGASE; LIPOPOLYSACCHARIDE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TRIPARTITE INTERACTION MOTIF PROTEIN; TRIPARTITE INTERACTION MOTIF PROTEIN 1; TRIPARTITE INTERACTION MOTIF PROTEIN 14; TRIPARTITE INTERACTION MOTIF PROTEIN 15; TRIPARTITE INTERACTION MOTIF PROTEIN 52; TRIPARTITE INTERACTION MOTIF PROTEIN 62; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LIGAND BINDING; LONG TERMINAL REPEAT; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; GENE KNOCKDOWN TECHNIQUES; HIV-1; HUMANS; IMMUNITY, INNATE; INTERFERONS; LEUKEMIA VIRUS, MURINE; MEMBRANE PROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; VESICULOVIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINE LEUKEMIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84871946152     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01804-12     Document Type: Article

References (76)

1. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A. 2001. The tripartite motif family identifies cell compartments. EMBO J. 20:2140-2151.
2. Han K, Lou DI, Sawyer SL. 2011. Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS Genet. 7:e1002388. doi: 10.1371/journal.pgen.1002388.
3. Short KM, Cox TC. 2006. Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding. J. Biol. Chem. 281:8970-8980.
4. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. 2011. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol. 23:46-56.
5. Sato T, Okumura F, Kano S, Kondo T, Ariga T, Hatakeyama S. 2011. TRIM32 promotes neural differentiation through retinoic acid receptormediated transcription. J. Cell Sci. 124:3492-3502.
6. Schwamborn JC, Berezikov E, Knoblich JA. 2009. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell 136:913-925.
7. Carthagena L, Bergamaschi A, Luna JM, David A, Uchil PD, Margottin- Goguet F, Mothes W, Hazan U, Transy C, Pancino G, Nisole S. 2009. Human TRIM gene expression in response to interferons. PLoS One 4:e4894. doi:10.1371/journal.pone.0004894.
8. El Bougrini J, Dianoux L, Chelbi-Alix MK. 2011. PML positively regulates interferon gamma signaling. Biochimie 93:389-398.
9. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
10. Nisole S, Stoye JP, Saib A. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 3:799-808.
11. Rajsbaum R, Stoye JP, O'Garra A. 2008. Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. Eur. J. Immunol. 38:619-630.
12. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.
13. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. 2008. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4:e16. doi:10.1371/journal.ppat.0040016.
14. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-394.
15. Lee K, KewalRamani VN. 2004. In defense of the cell: TRIM5alpha interception of mammalian retroviruses. Proc. Natl. Acad. Sci. U. S. A. 101: 10496-10497.
16. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
17. Yap MW, Nisole S, Lynch C, Stoye JP. 2004. Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U. S. A. 101:10786-10791.
18. Geoffroy MC, Chelbi-Alix MK. 2011. Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31:145-158.
19. Barr SD, Smiley JR, Bushman FD. 2008. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 4:e1000007. doi:10.1371/journal.ppat.1000007.
20. Gao B, Duan Z, Xu W, Xiong S. 2009. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50:424-433.
21. Hattlmann, C. J., J. N. Kelly, S. D. Barr. 2012. TRIM22: A diverse and dynamic antiviral protein. Mol. Biol. Int. 2012:153415. doi:10.1155/2012/153415.
22. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E. 2011. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J. Virol. 85:5183-5196.
23. Wolf D, Goff SP. 2007. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 131:46-57.
24. Keeble AH, Khan Z, Forster A, James LC. 2008. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc. Natl. Acad. Sci. U. S. A. 105:6045-6050.
25. Taylor RT, Lubick KJ, Robertson SJ, Broughton JP, Bloom ME, Bresnahan WA, Best SM. 2011. TRIM79alpha, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe 10:185-196.
26. Wang J, Liu B, Wang N, Lee YM, Liu C, Li K. 2011. TRIM56 is a virusand interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection. J. Virol. 85:3733-3745.
27. Kawai T, Akira S. 2011. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol. Med. 3:513-527.
28. Ozato K, Shin DM, Chang TH, Morse HC III. 2008. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8:849-860.
29. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, Wu X, Tao Z, Li Z, Cai X, Sun S, Xiang C, Sun B. 2008. TRIM30 alpha negatively regulates TLRmediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat. Immunol. 9:369-377.
30. Li Q, Yan J, Mao AP, Li C, Ran Y, Shu HB, Wang YY. 2011. Tripartite motif 8 (TRIM8) modulates TNFalpha- and IL-1beta-triggered NFkappaB activation by targeting TAK1 for K63-linked polyubiquitination. Proc. Natl. Acad. Sci. U. S. A. 108:19341-19346.
31. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambio-De Castillia C, Mothes W, Pizzato M, Grutter MG, Luban J. 2011. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472:361-365.
32. Tareen, SU, M. Emerman. 2011. Human Trim5alpha has additional activities that are uncoupled from retroviral capsid recognition. Virology 409:113-120.
33. Oke V, Wahren-Herlenius M. 2012. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J. Autoimmun. 39:77-82.
34. Zha J, Han KJ, Xu LG, He W, Zhou Q, Chen D, Zhai Z, Shu HB. 2006. The Ret finger protein inhibits signaling mediated by the noncanonical and canonical IkappaB kinase family members. J. Immunol. 176:1072-1080.
35. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916-920.
36. Arimoto K, Funami K, Saeki Y, Tanaka K, Okawa K, Takeuchi O, Akira S, Murakami Y, Shimotohno K. 2010. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc. Natl. Acad. Sci. U. S. A. 107:15856-15861.
37. Poole E, Groves I, MacDonald A, Pang Y, Alcami A, Sinclair J. 2009. Identification of TRIM23 as a cofactor involved in the regulation of NFkappaB by human cytomegalovirus. J. Virol. 83:3581-3590.
38. Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, Kawai T, Akira S. 2010. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 33:765-776.
39. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713.
40. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK. 2009. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325:1134-1138.
41. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A. 1997. IKK-1 and IKK-2: Cytokine-activated IκB kinases essential for NF-κB activation. Science 278:860-866.
42. Diaz-Griffero F, Qin XR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, Lienlaf M, Yokoyama S, Sodroski J. 2009. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. J. Virol. 83:10737-10751.
43. Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A. 2007. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128: 369-381.
44. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. 2004. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 101:5634-5639.
45. Wang CY, Mayo MW, Baldwin AS, Jr. 1996. TNF- and cancer therapyinduced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787.
46. Wick M, Lucibello FC, Muller R. 1992. Inhibition of Fos- and Rasinduced transformation by mutant Fos proteins with structural alterations in functionally different domains. Oncogene 7:859-867.
47. Wertz, I. E., V. M. Dixit. 2010. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb. Perspect. Biol. 2:a003350. doi:10.1101/ cshperspect.a003350.
48. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3:667-672.
49. Horng T, Barton GM, Flavell RA, Medzhitov R. 2002. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420:329-333.
50. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. 2008. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferonbeta. Nat. Immunol. 9:361-368.
51. Takeda K, Akira S. 2004. TLR signaling pathways. Semin. Immunol. 16:3-9.
52. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643.
53. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373-384.
54. Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K, Akira S. 2003. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171:4304-4310.
55. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S. 2002. Efp targets 14-3-3[sigma] for proteolysis and promotes breast tumour growth. Nature 417:871-875.
56. Kano S, Miyajima N, Fukuda S, Hatakeyama S. 2008. Tripartite motif protein 32 facilitates cell growth and migration via degradation of Ablinteractor 2. Cancer Res. 68:5572-5580.
57. Zhang J, Hu MM, Wang YY, Shu HB. 2012. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J. Biol. Chem. 287: 28646-28655.
58. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. 2009. DEAR1 is a dominant regulator of acinar morphogenesis and an indepen dent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 6:e1000068. doi:10.1371/journal.pmed.1000068.
59. Han KJ, Su X, Xu LG, Bin LH, Zhang J, Shu HB. 2004. Mechanisms of the TRIF-induced interferon-stimulated response element and NFkappaB activation and apoptosis pathways. J. Biol. Chem. 279:15652-15661.
60. Hasan UA, Caux C, Perrot I, Doffin AC, Menetrier-Caux C, Trinchieri G, Tommasino M, Vlach J. 2007. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc. Natl. Acad. Sci. U. S. A. 104:8047-8052.
61. Berg RK, Melchjorsen J, Rintahaka J, Diget E, Soby S, Horan KA, Gorelick RJ, Matikainen S, Larsen CS, Ostergaard L, Paludan SR, Mogensen TH. 2012. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS One 7:e29291. doi:10.1371/journal.pone.0029291.
62. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, Laughrea M, Wainberg MA, Hiscott J. 2011. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J. Virol. 85:1224-1236.
63. Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist WI, Yeager M. 2011. Hexagonal assembly of a restricting TRIM5alpha protein. Proc. Natl. Acad. Sci. U. S. A. 108:534-539.
64. Moscat J, Diaz-Meco MT, Wooten MW. 2007. Signal integration and diversification through the p62 scaffold protein. Trends Biochem. Sci. 32:95-100.
65. Zhang F, Hatziioannou T, Perez-Caballero D, Derse D, Bieniasz PD. 2006. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353:396-409.
66. Liberatore RA, Bieniasz PD. 2011. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 108:18097-18101.
67. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P. 2009. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83:3719-3733.
68. Galvin SR, Cohen MS. 2004. The role of sexually transmitted diseases in HIV transmission. Nat. Rev. Microbiol. 2:33-42.
69. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, Hahn BH, Allen SA, Derdeyn CA, Hunter E. 2009. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 5:e1000274. doi:10.1371/journal.ppat.1000274.
70. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT. 2009. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458:1034-1038.
71. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371.
72. O'Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, Rolnitzky L, Markowitz M, Margolis DM, Levy D, Bhardwaj N. 2011. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J. Clin. Invest. 121:1088-1101.
73. Goujon C, Malim MH. 2010. Characterization of the alpha interferoninduced postentry block to HIV-1 infection in primary human macrophages and T cells. J. Virol. 84:9254-9266.
74. Herbeuval JP, Shearer GM. 2007. HIV-1 immunopathogenesis: how good interferon turns bad. Clin. Immunol. 123:121-128.
75. Boasso A, Royle CM, Doumazos S, Aquino VN, Biasin M, Piacentini L, Tavano B, Fuchs D, Mazzotta F, Lo Caputo S, Shearer GM, Clerici M, Graham DR. 2011. Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis. Blood 118:5152-5162.
76. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, Wolinsky SM, Detels R. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.